C&EN White Paper
Powering up antibody-drug conjugates with PROTACs

Brought to you by Syngene International

Antibody-drug conjugates (ADCs) are one of the fastest growing areas of targeted cancer therapies. These drugs contain an antibody linked to a cell-killing small molecule. Their therapeutic success depends on balancing these three components during synthesis.

In this white paper, you’ll learn about approaches to ADC preparation, the potential for enhanced target specificity with antibodies carrying PROTACs, and how partnerships with CDMOs support continued innovation for this class of compounds.

Key Objectives:
  • Synthetic challenges when preparing ADCs.
  • How an ADC’s payload delivery, potency, and release properties depend on the balance of its components.
  • The latest research about antibody-PROTAC conjugates.

Brought to you by:
Syngene International
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2023 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy